Aim: Current estimates of the human epidermal growth factor receptor 2 (HER2)-positivity rate in gastric cancer vary widely in the literature, and there are limited data from countries in Asia. The primary aim of this study was to conduct a clinical audit of laboratories across seven countries in Asia to determine the incidence of HER2-positive gastric cancer in this region. Methods: Pathologists were asked to collect data on patient gender, age, cancer site, specimen type, tumor spread, type and grade, HER2 test results, including protein and/or gene copy enumeration, and final HER2 status on consecutive gastric cancer cases tested for HER2 in their laboratory over a 2-year period. Results: HER2 results from 5,301 gastric cancers were submitted by 50 laboratories. The overall HER2-positivity rate was 9.7% which, after the exclusion of China, increased to 18.1%. The rate between countries ranged from 0% to 23.1%, and from 0% to 50.0% between laboratories. An equivocal HER2 result was recorded in 19.5% of cases. Conclusion: Despite the lack of centralized testing to confirm the accuracy of HER2 diagnoses, the incidence of HER2-positive gastric cancer observed here was comparable to that reported in the literature. Nevertheless, rates were highly variable between countries and laboratories, which suggests a lack of HER2 testing expertise in gastric cancer. Given that the mortality rates for gastric cancer in Eastern Asia are the highest in the world, efforts should focus on improving HER2 testing expertise in the region so that patients receive the appropriate treatment early in their disease.
INTRODUCTION
Gastric cancer, which includes gastroesophageal junction (GEJ) cancer, is the fifth most common malignancy in the world, with an estimated 952,000 new cases diagnosed in 2012.
1 It is the third leading cause of cancer death in both sexes, and more than 70% of cases occur in developing countries with half occurring in Eastern Asia, mostly in China. 1 In Eastern Asia, gastric cancer is the second most the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
common malignancy after lung cancer, and the third leading cause of death. 1 The estimated mortality rates in Eastern Asia, the highest in the world, are 24 per 100 000 in men and 9.8 per 100 000 in women. 1 Globally, incidence and mortality are declining, but 5-year relative survival rates for metastatic gastric cancer remain poor (4.5%). 2, 3 These statistics demonstrate that gastric cancer represents a significant health burden in Asia.
The incidence and mortality of gastric cancer varies according to the geographical area in Asia. These variations are closely related to the prevalence of gastric cancer risk factors, especially Helicobacter pylori infection and its molecular virulence factors. 4 Other contributing factors may include differences in dietary patterns, salt intake, and smoking. 5 The presence of screening programs clearly impact survival rates. 6, 7 In countries with these programs, such as Korea and Japan, gastric cancer is more likely to be diagnosed at an early stage, resulting in more favorable 5-year survival rates of 55.6−66.0%, 8 and 50.0%, respectively. 9 Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase receptor that plays a pivotal role in growth factor signal transduction pathways leading to cell survival, division, and differentiation. 10, 11 The reported rate of overexpression of the HER2 receptor in gastric cancer varies widely in the literature between 7% and 34%. 7, [12] [13] [14] [15] The prognostic value of the HER2 oncogene in gastric carcinomas is controversial with some studies identifying it as a negative prognostic factor for survival, some as positive, and others failing to find a relationship. 12, [16] [17] [18] The correlation between HER2-positivity and poorer outcomes has been evidenced by higher HER2-positivity rates in advanced gastric carcinomas and prognostic significance found in early gastric carcinomas. 17, 19 However, other studies have cast doubt on this. 17 With regards to the predictive value of HER2 in response to biological treatments targeting the receptor, HER2 overexpression has been shown to be a clear predictor of response to HER2-targeted therapy. 20 For this reason, HER2 can be considered a valid therapeutic target and patients with gastric or GEJ cancer are recommended to undergo testing for HER2 at the time of initial diagnosis to inform decision-making options. 7 The Trastuzumab for Gastric Cancer (ToGA) trial was an open-label, international, phase III, randomized controlled trial that investigated trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or GEJ cancer. 20 Results showed that in patients with high HER2 expression (immunohistochemistry [ 20 ToGA data emphasized the need for high-quality, accurate, and standardized HER2 testing to ensure identification of the patient population that will benefit from trastuzumab. Based on the results of the ToGA trial, IHC is the primary test in gastric and GEJ cancer, with FISH or silver in situ hybridization being used as a reflex test in cases with an equivocal IHC 2+ result. 7, 20 To date, trastuzumab is the only targeted therapy approved for the first-line treatment of patients with HER2-positive metastatic gastric cancer which prolongs survival beyond 12 months. 20, 21 Until recently, recommendations on HER2 testing in gastric cancer have been primarily based on testing experience in Europe. 7 However, it has become increasingly apparent that Asia-Pacific-specific guidelines are needed to account for the difference in testing environments and challenges faced by laboratories in the region. The resulting publication by Kim et al. was developed by a multidisciplinary panel of experts from the Asia-Pacific region, who actively work and provide education for HER2 testing in gastric cancer. 6 The recommendations highlight and clarify aspects of testing that are of particular relevance to the region, and emphasize the unique features of gastric carcinomas compared with breast carcinomas that must be taken into account during HER2 testing. 6 Across Asian populations, HER2 overexpression in gastric cancer is reported in approximately 9.8−23.0% of cases, 14, 19, [22] [23] [24] [25] [26] with higher rates generally observed in GEJ cancer. 23, 24 Such high variability in HER2-positivity rates is likely due to the different testing environments and practices between and within countries; for instance, the use of non-validated testing kits, or pathologists' inexperience with HER2 testing in gastric cancer. Lack of access to HER2 testing is also a barrier to accurately determining the true incidence of HER2-positive gastric cancer in countries in this region. A number of studies have investigated HER2-positivity rates in China, 23, 24, 27 Korea 14, 19, 22 and Japan, 25 but there is limited information from other Asian countries.
The Scientific Partnership for HER2 testing Excellence (SPHERE) is an educational initiative that promotes and facilitates excellence in HER2 testing in breast and gastric cancer across Asia Pacific. SPHERE aims to ensure that more patients receive an accurate diagnosis and appropriate treatment, by encouraging best practice to improve the reliability and reproducibility of HER2 testing, and the accuracy of interpretation. SPHERE also aims to enhance multidisciplinary collaboration between pathologists, technicians, surgeons and oncologists. Established in 2010, SPHERE has held numerous educational forums and pathology workshops across the region, as well as allied activities to support HER2 testing. The latter include partnership with the UK National External Quality Assessment Service (UK NEQAS), the external quality assurance program based in London.
In 2011, SPHERE established a clinical audit to monitor the performance of testing laboratories in Asia, and to define reference values for expected HER2-positivity rates among both breast and gastric cancer patients in the region. Monitoring HER2-positivity rates helped identify laboratories with inadequate testing procedures, and supported the development of targeted training programs for laboratories in this region. The findings of the breast cancer audit have been published separately. 28 We present findings on the incidence of HER2-positive gastric cancer diagnosed in laboratories participating in a clinical audit across seven countries in Asia. This study also explored the relationship of HER2-positive gastric cancer status with a number of parameters, including cancer site, specimen type and tumor spread, type, and grade.
MATERIALS AND METHODS

Study design
Pathology laboratories from China, Hong Kong, Malaysia, The Philippines, Taiwan, Thailand, and Vietnam were invited to submit data on gastric cancer patients tested for HER2 between October 2011 and October 2013. Laboratories willing to participate were provided with a unique reference code to guarantee confidentiality. Pathologists were asked to collect data on patient gender, age, cancer site, specimen type, tumor spread, tumor type, tumor grade, HER2 test results, including protein and/or gene copy enumeration, and final HER2 status on consecutive gastric cancer cases tested for HER2 in their laboratory. At the time of the study tumor stage was not known.
Participating laboratories were provided with a SPHERE Regional HER2 Testing Audit Protocol, which detailed the design, implementation, and data analysis of the audit. They were required to submit a copy of their validated HER2 testing protocols along with a participation agreement. Any deviations from testing protocols were to be communicated directly to a third party agency.
Data were submitted in a Microsoft Excel spreadsheet to the third party agency for collation on a monthly basis. Patient data that were submitted without a HER2 result or a final HER2 status were excluded from the study. This audit was approved by the Institutional Review Boards of participating centers, and was conducted in accordance with the Declaration of Helsinki and local requirements.
HER2 testing
Pathology laboratories were required to establish, validate, and adhere to HER2 testing protocols based on recommendations developed and provided by SPHERE. SPHERE recommendations for the classification of HER2 status in gastric cancer followed the recommended HER2 testing algorithm for gastric cancer, developed as a result of the ToGA trial. 20 Consequently, HER2-positivity was defined as IHC 2+ and FISH-positive or IHC 3+. 20 Laboratories' HER2 testing protocols were collected and reviewed prior to data collection. The majority of pathologists from participating laboratories had attended SPHERE tutorials and workshops, which provided training on HER2 testing procedures and the accurate interpretation of IHC and in situ hybridization (ISH) results.
Statistical analysis
For each laboratory, the percentage of patients who were reported as HER2-positive, HER2-equivocal (i.e. patients for whom confirmatory ISH testing was not performed and hence the final diagnosis was recorded as IHC 2+), or HER2-negative was calculated. The true percentage of HER2-positive gastric cancer patients at each laboratory may vary due to inter-laboratory variables, such as testing method and interpretation, genetic traits of the respective patient populations, or sample referral practices between laboratories within a country. Therefore, each laboratory represents a clustered sample of patients from its respective patient populations. As a result, the usual countrywide estimate of the standard deviation for HER2-positive patients would be an underestimation of the true standard deviation. Thus, for each country, the percentage of patients who were HER2-positive was estimated as a weighted average of the percentage of HER2-positive patients at each laboratory, with weights being inversely proportional to their respective variance. The method of moments 29 was used to estimate the variance of the percentage of patients who were HER2-positive for each country, and 95% CIs were derived based on these estimators. The percentage of patients who were HER2-equivocal or HER2-negative was estimated with identical methods.
For each country and tumor grade, the percentage of patients who were HER2-positive was estimated as a weighted average of the percentage of HER2-positive patients at each laboratory, with weights being inversely proportional to their respective variance. The same method was applied to cancer site, specimen type, tumor spread, and tumor type. China did not report HER2-positivity by age or gender due to patient data confidentiality restrictions; therefore, an overall analysis of HER2-positivity by age and gender was not appropriate for such small frequencies. The HER2-positivity rate and 95% CI is presented for each country, and the region overall, as a forest plot in Figure 1 .
RESULTS
Patient and tumor characteristics
Over a 2-year period, data on 5,301 gastric cancer patients were collected from 50 laboratories; 15 patients were excluded due to incomplete HER2 testing data being provided. The majority of patients were from China (n = 4,018, 76.0%), followed by Taiwan (n = 757, 14.3%), Hong Kong (n = 253, 4.8%), and Vietnam (n = 206, 3.9%). With regards to age, 15.6% were >60 years, 9.1% were between 41 and 60 years, and 0.9% were <40 years (Table 1) . Age was not reported for 74.4% of patients, almost all of whom were from China. Of all patients, 17.2% were male and 8.4% were female; gender was not reported for 74.4% of patients, primarily from China. The gastric region was reported as the cancer site in 73.1% of patients and the GEJ in 10.1% of patients. Gastric cancer site was not reported for 16.8% of patients.
In Hong Kong, Malaysia and Thailand, the majority of patients had a biopsy; in China, Taiwan and Vietnam, the majority of patients underwent excision of the tu- 
HER2 status by country and region
HER2 results were obtained from 5,286 gastric cancer specimens, ranging from six in Malaysia to 4018 in China. The average number of cases per laboratory was 106. Overall HER2-positivity rate for the region was 9.7% (95% CI, 7.84−11.65; Table 2 ). The HER2-positivity rate between countries ranged from 0% in Malaysia and the Philippines to 23.1% (95% CI, 17.91−28.27) in Hong Kong (Fig. 1) Table 2 also shows the HER2 status for all countries combined except China. When excluding China, the overall HER2-positivity rate increased from 9.7% to 18.1% (95% CI, 11.63−24.54). The HER2-equivocal and HER2-negativity rate decreased to 13.8% (95% CI, 7.38−20.22) and 70.9% (95% CI, 60.64−81.18), respectively, when compared with all countries combined. For China, the combined HER2-positivity rate across the 39 laboratories was 8.0% (95% CI, 6.35−9.68).
HER2-positivity rate and gastric cancer site
Data on HER2 status and gastric cancer site were obtained from 4410 (83.4%) patients. The overall HER2-positivity rate for patients characterized as having a gastric site was 9.8% (95% CI, 7.68−11.87), and 16.8% (95% CI, 13.54−20.08) for those with a GEJ site ( Table 3) . The results for Malaysia, the Philippines, and Thailand were not summarized due to absence of HER2-positive patients or because the frequencies were too small to permit the calculation of the clustered variance. After excluding China, the remaining countries combined (Hong Kong, Taiwan, Vietnam) showed an 
HER2-positivity rate and specimen type
Data on HER2 status and specimen type were obtained from 5286 (100.0%) patients. The overall HER2-positivity rate for patients with a biopsy specimen was 30.7% (95% CI, 20.24-41.21), and 9.5% (95% CI, 7.59−11.32) for an excision (Table 3) . After excluding China, the remaining countries combined (Hong Kong, Taiwan, Vietnam) showed an increase in HER2-positivity rate for the specimen site: 55.5% (95% CI, 28.59−82.50) for a biopsy, and 17.7% (95% CI, 11.38−23.92) for an excision.
HER2-positivity rate and tumor spread
Data on HER2 status and tumor spread were obtained from 3701 (70.0%) patients. The overall HER2-positivity rate was 9.5% (95% CI, 7.58−11.50) for advanced disease (Stage 3), and 15.0% (95% CI, 10.18−19.90) for those with metastatic disease (Stage 4; Table 3 ). After excluding China, the remaining countries combined (Hong Kong, Taiwan, Vietnam) showed an increase in HER2-positivity for tumor spread: 16.8% (95% Frequencies were too small to permit the calculation of the clustered variance. The results for Malaysia, the Philippines and Thailand were not summarized as there were no HER2-positive patients, or the frequencies were too small to permit the calculation of the clustered variance. CI, confidence interval; GEJ, gastroesophageal junction; HER2, human epidermal growth factor receptor 2.
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Statistical significance of HER2-positivity rates between subgroups
The chi-squared (χ 2 ) test was used to assess the statistical significance of HER2-positivity rates across the different demographic parameters for the following subgroups: gastric cancer site, specimen type, tumor spread, tumor type, and tumor grade. For all analyses, the χ 2 test was highly significant (P < 0.0001), concluding that there was at least one significant difference between the HER2-positive rates and the demographic parameters of the individual subgroups.
DISCUSSION
This study describes findings from the largest clinical audit of HER2 testing in gastric cancer in Asia, providing the first insight into the rate of HER2-positive gastric cancer, and the current standard of HER2 testing among laboratories in this region. Based on an analysis of 5286 gastric cancer specimens, an overall HER2-positivity rate of 9.7% was observed. This rate is similar to the range reported in the literature for Asian populations (9.8−23.0%). 14, 19, [22] [23] [24] [25] [26] The rate of HER2-positivity varied considerably between countries, and between laboratories within the same country.
To assess the impact of the China data on these analyses (76.0% of data were from China), a further analysis was performed for all countries combined excluding China. Consequently, the overall HER2-positivity rate increased from 9.7% to 18.1%, a rate that is closer to that seen for Asian patients in the ToGA trial (23.9%). 15 Variance in HER2-positivity rates between and within countries may be explained in part by the proportion of carcinomas with certain characteristics with which HER2-positivity has been correlated. HER2-positivity rates were higher in the GEJ cancer site than in the gastric site (16.8% vs 9.8%), a correlation that has been consistently reported in the literature. 15, 23, 24 In addition, higher rates of HER2-positivity were reported in biopsy specimens than for excisions (30.7% vs 9.5%), which is consistent with findings from the ToGA study, wherein HER2-positivity rates for biopsy specimens were also higher than for excisions (23.2% vs 19.7%). 15 It is generally agreed that biopsies are preferable to surgical specimens for optimal testing results due to biopsies having more standardized fixation conditions, 7 and this may reflect the differences in HER2-positivity rates seen in this study. Consistent with previous reports, 23, [30] [31] [32] [33] [34] HER2-positivity was more frequent with well-or moderately differentiated carcinomas (24.0% and 16.0%, respectively), compared with poorly differentiated carcinomas (7.6%).
Interestingly, contrary to consistent findings previously reported for both Western and Asian populations, 14, 15, 19, 23, 27, 35 HER2-positivity rates were higher for the diffuse-type tumors (20.4%) compared with intestinal-and mixed-type tumors (17.2% and 11.6%, respectively). Further study of diffuse-type tumors using ISH to evaluate the HER2 gene copy number and HER2/chromosome enumeration probe 17 (CEP17) ratio is needed to accurately categorize these tumors. HER2-positivity rates were higher in metastatic disease compared with advanced disease (15.0% vs 9.5%).
The high variability in HER2-positivity rates between and within countries is likely influenced by differences in testing practices, such as the use of nonvalidated tests or unfamiliarity with the gastric cancer HER2 testing guidelines. 7 Although all participating laboratories were provided with comprehensive training prior to the audit, these differences reflect a need for continued participation in proficiency testing programs to identify potential errors in HER2 assessment, and for the standardization of grading and tumor classification practices. SPHERE partners with the external quality assurance program, UK NEQAS, which provides practical assistance to laboratories, consultation on troubleshooting sources of testing variation, and guidance to improve testing quality. Participation in such programs is strongly recommended for the accuracy and consistency of HER2 testing results. 7 In addition to differences in testing practices, the high variability in HER2-positivity rates between countries is also influenced by the country-specific nature of gastric cancer. Thus, contribution of the nature of disease in each country cannot be excluded as a possible influence on the variable HER2 results seen in our study.
A number of limitations of this study warrant mention. Most notably, a considerable amount of patient data were not collected, particularly on tumor stage, age and gender, preventing further analysis of these parameters. The main reason for this deficit was due to patient data confidentiality restrictions in China. This is one example of the considerable challenges faced in obtaining data in this region; there are hugely different testing environments and practices between and within countries, as well as differing data protection and ethics regulations.
There was no centralized testing to confirm the accuracy of HER2 diagnosis and grading, because it was considered impractical to validate the diagnosis of over 5,000 tumor samples obtained from multiple laboratories across Asia. However, all participating laboratories were required to submit their own validated HER2 testing protocols, and validation of test results was repeatedly emphasized during training in the SPHERE program.
The high proportion of equivocal (IHC 2+) HER2 cases is also a concern. Many patients in Asian countries are not referred for confirmatory ISH testing, primarily due to the high cost of these assays. In addition, oncologists may be reluctant to obtain a final HER2 result for patients that are unable to afford HER2-targeted therapy should a HER2-positive result be found.
Given these limitations it is probably unwise to consider these results as a wholly accurate representation of the incidence of HER2-positive gastric cancer in Asia. However, in highlighting the variation in HER2 results between countries, and importantly between laboratories within the same country, this audit has drawn attention to the need for ongoing training of pathologists and laboratory staff and provision of access to additional testing in order to provide a final result for IHC 2+ equivocal cases.
This is the first study to provide an insight into the rate of HER2-positive gastric cancer across Asia. Given the significant burden of gastric cancer in Asia, these data are important to increase understanding and awareness of the disease and issues faced by HER2 laboratories in these countries. Increased education and awareness of HER2 testing in gastric cancer, as well as improved early detection are needed to improve outcomes for these patients.
